FDA approval of IDVYNSO gives Merck a fresh HIV story, but will clinicians switch stable patients?
Merck’s IDVYNSO has won FDA approval in HIV. Read what the new two-drug regimen changes, where it fits, and what risks still matter.
Pharma & Biotech
Pharma & Biotech
Gilead expands its HIV playbook as lenacapavir moves from niche drug to platform strategy
Gilead’s CROI 2026 data highlight lenacapavir’s evolution into a platform for HIV treatment and prevention. Explore what this changes for clinicians and regulators.